Back

Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering and cardiovascular outcomes Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Kunal Mahajan

Himachal Heart Institute, Mandi (India)

6 More presentations in this session

Presentation thumbnail
Gender-related differences in efficacy, safety and adherence of PCSK9 inhibitors in real-world clinical practice: insights from the AT-TARGET-IT Registry
Professor P. Perrone-Filardi (Naples, IT)
Abstract Slides Video
Presentation thumbnail
EDP167, an ANGPTL3-target siRNA, showed favorable safety and lipid-lowering potential in Chinese healthy adult volunteers and subjects with mild dyslipidemia
Doctor B. Jiang (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Statin therapy and 1-year mortality in non-ischaemic acute myocardial injury: a dual-cohort study
Doctor T. Yang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials
Mr M. De Kleer (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Effect of apolipoprotein B reduction on major adverse cardiovascular events in randomized controlled trials of triglyceride-lowering therapies: systematic review and exploratory meta-regression
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid lowering and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparative effectiveness of lipid-lowering regimens for achieving ESC LDL-cholesterol targets in acute coronary syndrome: a real-world cohort analysis
31 August 2026
thumbnail
Congress Session
Getting to LDL-C goals and staying there long-term
28 August 2022
thumbnail
Congress Presentation
LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy
28 August 2026
thumbnail
Congress Presentation
Successful ESC recommended LDL-C reduction after percutaneous coronary intervention: real-world data from the contemporary ZON-HR registry.
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources